Gilead Sciences Inc.

GILD-Q

NASDAQ:GILD

59.89
0.22 (0.37%)
Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
More at Wikipedia

Analysis and Opinions about GILD-Q

Signal
Opinion
Expert
SELL STRENGTH
SELL STRENGTH
November 13, 2020

It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.

Show full opinionHide full opinion

It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.

WATCH
WATCH
October 30, 2020
Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
Show full opinionHide full opinion
Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
TOP PICK
TOP PICK
October 27, 2020
Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
Show full opinionHide full opinion
Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
DON'T BUY
DON'T BUY
October 23, 2020
It has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
Show full opinionHide full opinion
It has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
DON'T BUY
DON'T BUY
October 20, 2020
Very disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
Show full opinionHide full opinion
Very disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
HOLD
HOLD
October 9, 2020
A big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
Show full opinionHide full opinion
A big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinion
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
COMMENT
COMMENT
March 20, 2020
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
Show full opinionHide full opinion
US Healthcare? Healthcare generally under-preforms in election years. A safer pick would be GILD, for their COVID-19 research and HIV drugs.
TOP PICK
TOP PICK
March 11, 2020

He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)

Show full opinionHide full opinion

He likes the yield. He believes they are making some headway on a CVT-19 drug on trial in China. They are also doing more M&A to bring innovation into their pipeline. They are working on liver disease drugs and HIV drugs. They have a clean balance sheet as well. Yield 3.68% (Analysts’ price target is $75.22)

DON'T BUY
DON'T BUY
February 25, 2020
It's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
Show full opinionHide full opinion
It's a little speculative, because they could invent the coronavirus vaccine. In the past they found the hepatitis C cure. Gilead did very well until a few years ago. Now, their earnings and stock are half of their historic peak.
DON'T BUY
DON'T BUY
January 30, 2020
It is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
Show full opinionHide full opinion
It is less of a diversified company than big pharma. He is not big on investment in this sector. It is a tough place to be. It would be better at a lower price.
DON'T BUY
DON'T BUY
January 17, 2020
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
Show full opinionHide full opinion
Very disappointing. The update from the new CEO wasn't particularly exciting. Their HIV prep drugs is doing well. However with the Hepatitis C drug coming off patent, they have lost revenues. Deep value but they need to execute. They like the high yield with great premiums on the options. He would rather own another diversified biotech or a basket.
HOLD
HOLD
August 27, 2019
A drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
Show full opinionHide full opinion
A drug company that was the poster boy for high prices for drugs including hep-C creating some bad sentiment. The company has a good pipeline on HIV drugs. It trades at less than 9 times earnings. The worst is behind them. Yield 4%
DON'T BUY
DON'T BUY
August 22, 2019

It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.

Show full opinionHide full opinion

It has been a bit of a value trap for years. They were effective in the cure for HEP-C. For them it has been a declining revenue steam. They made an acquisition that did not work out. Revenues have dropped 40% over the last 5 years. He would stay clear of it.

BUY
BUY
July 17, 2019
It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
Show full opinionHide full opinion
It's been painful as it consolidates for the past 18 months. They have a hepatitis franchise, an expensive drug, that came off patent. Gilead failed to reinvest those profits, too. Their HIV franichise is doing very well. They acquired some companies, which look promising. The CEO is doing a good job. They are trading 9.5x fowarding earnings. Great dividend yield and balance sheet.
Showing 1 to 15 of 244 entries

Gilead Sciences Inc.(GILD-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 6

Total Signals / Votes : 7

Stockchase rating for Gilead Sciences Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions

What is Gilead Sciences Inc. stock symbol?

Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q

Is Gilead Sciences Inc. a buy or a sell?

In the last year, 7 stock analysts published opinions about GILD-Q. 0 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is SELL ON STRENGTH. Read the latest stock experts' ratings for Gilead Sciences Inc..

Is Gilead Sciences Inc. a good investment or a top pick?

Gilead Sciences Inc. was recommended as a Top Pick by Jim Cramer - Mad Money on 2020-11-13. Read the latest stock experts ratings for Gilead Sciences Inc..

Why is Gilead Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Gilead Sciences Inc. worth watching?

7 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.

What is Gilead Sciences Inc. stock price?

On 2020-11-23, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $59.89.